You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 1-20 of 64 results found

Method for HLA LOH Detection in Liquid Biopsies

The National Cancer Institute (NCI) seeks research co-development partners for a companion diagnostic (CDx) that detects human leukocyte antigen (HLA) loss-of-heterozygosity (LOH) and other biomarkers to predict efficacy of TCR-T cell adoptive transfer, immune checkpoint inhibition (ICI), tumor infiltrating lymphocytes (TIL), and other TCR-mediated immunotherapies.
  • Diagnostics

Method for HLA LOH Detection in Liquid Biopsies

The National Cancer Institute (NCI) seeks research co-development partners for a companion diagnostic (CDx) that detects human leukocyte antigen (HLA) loss-of-heterozygosity (LOH) and other biomarkers to predict efficacy of TCR-T cell adoptive transfer, immune checkpoint inhibition (ICI), tumor infiltrating lymphocytes (TIL), and other TCR-mediated immunotherapies.
  • Diagnostics

Methods of Determining Homeostatic Perturbations

The Eunice Kennedy Shriver National Institute of Child Health and Human Development seeks research co-development partners and/or licensees to further develop and commercialize its methods of noninvasively and directly determining the absolute homeostatic state, metabolic activity, function, and viability of isolated cells, or tissues (ex vivo or in vivo), such as the Central Nervous System (CNS). The method uses Nuclear Magnetic Resonance or Magnetic Resonance Imaging measurements of the rate at which endogenous water exchanges across cell membranes.
  • Diagnostics

Tamperless Tensor Elastography Imaging

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of tamperless tensor elastography imaging in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications.
  • Diagnostics

Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of diffusion tensor distribution imaging (DTD-MRI) in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications.
  • Diagnostics

Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method

The National Eye Institute seeks research and co-development partners and/or licensees to: (1) advance the production and uses of the new RNA preparation method; (2) manufacture reagent kits for testing in patients with suspected COVID-19 and other DNA/RNA viruses, and (3) manufacture reagent kits for patient biomarker profiles and inherited disease diagnostics.
  • Diagnostics

Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome

Scientists at the National Cancer Institute (NCI) have developed SELECT (synthetic lethality and rescue-mediated precision oncology via the transcriptome), a computational precision-oncology framework harnessing genetic interactions to improve treatment options for cancer patients. NCI seeks collaborators or licensees to advance the development of this technology into precision diagnostics.
  • Diagnostics

CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles

Scientists at the National Cancer Institute (NCI) have developed the Cytokine Signaling Analyzer (CytoSig), a software-based platform that provides both a database of target genes modulated by cytokines and a predictive model of cytokine signaling cascades from transcriptomic profiles. NCI seeks collaborators or licensees to advance the development of CytoSig for research, target discovery, or as a Clinical Decision Support System (CDSS).
  • Diagnostics
  • Research Tools

RNASEH-Assisted Detection Assay for RNA

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the development and commercialization of a diagnostic assay that detects sequence-specific (viral) RNA.
  • Diagnostics

Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens

Researchers at the National Cancer Institute (NCI) have developed a gene-expression profiling-based molecular diagnostic assay to diagnose and classify primary mediastinal large B cell lymphoma (PMBCL) from diffuse large B cell lymphoma (DLBCL). The diagnosis can be done using routinely available formalin-fixed, paraffin-embedded (FFPE) biopsies. The NCI seeks licensees and/or co-development partners to commercialize this technology.
  • Diagnostics

A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma

Researchers at the National Cancer Institute (NCI) identified a biomarker signature of viral infection that correlates with hepatocellular carcinoma (HCC) incidence in at-risk individuals. It has been validated in a longitudinal cohort to detect HCC with high sensitivity and specificity up to 7 years prior to clinical diagnosis. This viral exposure signature can be easily implemented into diagnostic assays for screening of HCC and is available for licensing and/or co-development opportunities.
  • Diagnostics

Gene-based Diagnostic Predicts Patient Response to Cancer Immunotherapy

Somatic mutations can alter the sensitivity of tumors to T-cell mediated immunotherapy. Identifying genes that positively regulate the sensitivity of cancer cells to T-cell mediated clearance is key for effective treatment in cancer patients. Researchers at the National Cancer Institute (NCI) have identified a panel of genes which are useful in predicting a patient’s response to immunotherapy. NCI seeks partners to co-develop or license the technology toward commercialization.
  • Diagnostics

Diagnostic Assay for Determining Patient Response to Apoptosis-related Cancer Therapy

Researchers at the National Cancer Institute (NCI) developed a multiplex assay to determine the efficacy of apoptosis-related drugs targeting the Bcl2 family of proteins or aid in the selection of cancer patients likely to respond. The NCI seeks partners for co-development or licensees for commercialization of novel immunoassays for determining or predicting patient response to cancer therapy.
  • Diagnostics

Quantitative In Vivo Methods for Measuring Brain Networks

Researchers at the NICHD seek licensing and/or co-development research collaborations for a Magnetic Resonance Imaging (MRI) method to quantitatively measure in vivo the estimated conduction time of nerve impulses in the brain.
  • Diagnostics

Methods for Single Cell Analysis of the Epigenome, Transcriptome, and Genome

There are currently no methodologies that allow for epigenome, genome and transcriptome analysis all in a single cell. In addition, there are currently no methodologies that permit repeating the results of these analyses on the same single cells. Scientists at the National Cancer Institute (NCI) Laboratory of Cellular Oncology have developed a method for generating a “reusable” single cell that allows for repeated experiments on the same cell. Utilizing this methodology epigenomic, genomic, and transcriptomic analysis can be performed on the same cell. NCI seeks parties to license or co-develop the technology through research collaborations.
  • Diagnostics

Pages